MedTrace Logo

HWS116 Monotherapy in Patients With Advanced Solid Tumors

NCT07413328 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-04-28

No results posted yet for this study

Summary

This is a Phase I open-label study that will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HWS116 monotherapy in patients with advanced solid tumors.

Conditions

Interventions

DRUG

HWS116 Injection

Administered intravenous infusion at pre-specified doses every two weeks.

Sponsors & Collaborators

  • Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-07
Primary Completion
2027-08-31
Completion
2028-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07413328 on ClinicalTrials.gov